



# US PATENT & TRADEMARK OFFICE

## PATENT FULL TEXT AND IMAGE DATABASE

[Help](#) | [Home](#) | [Boolean](#) | [Manual](#) | [Number](#) | [Order Copy](#) | [PTOLE](#)  
[Bottom](#) | [Shopping Cart](#)

Searching 1976-2000...

**Results of Search in 1976-2000 db for:**

**"OM-10.1": 20 patents.**  
**Hits 1 through 20 out of 20**

[Jump To](#)

[Refine Search](#)

PAT. NO.	Title
1 6,046,175	<a href="#">Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis</a>
2 5,914,331	<a href="#">Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane</a>
3 5,905,070	<a href="#">5--Caboxamido or 5--fluoro!--&gt;2', 3'--unsaturated or 3'--modified!--pyrimidine nucleosides</a>
4 5,892,025	<a href="#">Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers</a>
5 5,852,027	<a href="#">Antiviral 1,3-dioxolane nucleoside analogues</a>
6 5,827,727	<a href="#">Method of resolution of 1,3-oxathiolane nucleoside enantiomers</a>
7 5,736,527	<a href="#">Method of treating HIV in humans by administration of ddi and hydroxycarbamide</a>
8 5,736,526	<a href="#">Mixtures of DDI and D4T with hydroxycarbamide for inhibiting retroviral replication</a>
9 5,728,575	<a href="#">Method of resolution of 1,3-oxathiolane nucleoside enantiomers</a>
10 5,703,069	<a href="#">Method for inhibiting and controlling viral growth</a>
11 5,703,058	<a href="#">Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent</a>
12 5,629,198	<a href="#">Anti-HIV agent</a>
13 5,612,330	<a href="#">Methods for inhibiting and controlling viral growth</a>
14 5,565,446	<a href="#">Benzothiophene, benzofuran and indole-thiazepinones, oxazepinones and diazepinones as inhibitors of cell adhesion and as inhibitors of HIV</a>
15 5,521,161	<a href="#">Method of treating HIV in humans by administration of ddi and hydroxycarbamide</a>
16 5,444,085	<a href="#">Methods of inhibiting HIV and inhibiting the activation of HIV</a>
17 5,434,188	<a href="#">1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV</a>
18 5,424,329	<a href="#">Indole-2-carboxamides as inhibitors of cell adhesion</a>
19 5,350,748	<a href="#">3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion</a>
20 5,256,534	<a href="#">CD4.sup.+ , latently HIV-1-infected hematopoietic progenitor cells</a>

[Top](#) | [Shopping Cart](#)

[Help](#) [Home](#) [Boolean](#) [Manual](#) [Number](#) [Order Copy](#) [PTOLs](#)


[SEARCH CATALOGS](#) | [SITE MAP](#) | [CONTACT US](#)

ORDER | PRODUCTS | PROGRAMS &amp; SERVICES

You may continue your word search on Cell Lines by typing in your search criteria below or go back to the [Cell Lines menu](#) and begin a new search. To choose another collection, go back to the main menu by clicking on "search catalogs" above. For complex searches, using boolean operators, the following characters must be used: & (for AND), | (for OR), ^ (for AND NOT). An asterisk (\*) is used as the wildcard. For more information please review the [Search Help](#).

OM-10.1



 For query options, please read the [search help](#).

Cell Lines	
<b>ATCC Number:</b>	CRL-10850 <input type="button" value="order this item"/>
<b>Organism:</b>	<i>Homo sapiens</i> (human)
<b>Designation:</b>	<b>OM-10.1</b>
<b>Depositors:</b>	The United States of America
<b>Tissue:</b>	acute promyelocytic leukemia; peripheral blood; human immunodeficiency virus (HIV) infected
<b>Products:</b>	human immunodeficiency virus 1 (HIV-1)
<b>Receptors Expressed:</b>	complement; Fc
<b>Morphology:</b>	lymphoblast
<b>Comments:</b>	The <b>OM-10.1</b> cell line was cloned from HL-60 cells (see ATCC CCL-240) which survived an acute infection with human immunodeficiency virus 1 (HIV-1). The cells have a minimal constitutive production of HIV-1, but HIV-1 expression can be increase 30 to 1000 fold by treatment with tumor necrosis factor alpha (TNF alpha) or with phorbol myristic acid (known to induce TNF alpha production in HL-60). The cells remain CD4 positive until the virus is activated, and superinfection will result in an increase in background virus expression (this can be reduced by periodic treatment with 10 mg/ml of AZT).
<b>Age Stage:</b>	36 years
<b>Ethnicity:</b>	Caucasian
<b>Gender:</b>	female
<b>Reverse Transcript:</b>	negative
<b>Growth Properties:</b>	suspension
<b>Antigen Expression:</b>	CD4 +
<b>Virus Susceptibility:</b>	human immunodeficiency virus 1 (HIV-1)
<b>Isoenzymes:</b>	G6PD, B; PGM1, 1; PGM3, 1; ES-D,1; Me-2, 1; AK-1, 1; GLO-1, 1
<b>Subculturing:</b>	Cultures can be maintained by addition or replacement of medium. Start new cultures at 5 X 10 exp5 viable cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml.

<b>Fluid Renewal:</b>	Every 2 to 3 days
<b>Freeze Medium:</b>	Culture medium, 92.5%; DMSO, 7.5%
<b>References:</b>	RF32486: Butera ST et al. CD4.sup.+ , latently HIV-1-infected hematopoietic progenitor cells. U.S. Pat. 5,256,534 dated Oct. 26, 1993 RF33105: Butera ST et al. Extrachromosomal human immunodeficiency virus type-1 DNA can initiate a spreading infection of HL-60 cells. J. Cell. Biochem. 45: 366-373, 1991 PubMed: 91258424 RF33153: Butera ST et al. Tumor necrosis factor receptor expression and signal transduction in HIV-1-infected cells. AIDS 7: 911-918, 1993 PubMed: 93363253 RF33260: Butera ST et al. Regulation of HIV-1 expression by cytokine networks in a CD4+ model of chronic infection. J. Immunol. 150: 625-634, 1993 PubMed: 93123765 RF33628: Besansky NJ et al. Unintegrated human immunodeficiency virus type 1 DNA in chronically infected cell lines is not correlated with surface CD4 expression. J. Virol. 65: 2695-2698, 1991 PubMed: 91202618 RF33630: Butera ST et al. Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J. Virol. 65: 4645-4653, 1991 PubMed: 91333004 RF34772: Antiviral. Chem. Chemother. 4: 55-63, 1992
<b>Propagation:</b>	ATCC medium: RPMI 1640 medium with 2 mM L-glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin, 90%; <u>heat-inactivated fetal bovine serum, 10%</u>
<b>BioSafety:</b>	Handle as potentially biohazardous material under at least Biosafety Level 3 containment.
<b>Patent Statement:</b>	This material is cited in a U.S. and/or other Patent and may not be used to infringe the patent claims.
<b>BioSafety Level:</b>	3
<b>Required Forms:</b>	Customer Acceptance of Responsibility
<b>Shipped:</b>	frozen
<b>Price:</b>	\$245
<b>Revised :</b>	Jan 07, 2000

**Pricing Note:**

All prices are in U.S. dollars and are for U.S. Profit & Foreign Institutions. Our domestic (U.S. and Canada) non-profit customer-pricing discount has also changed and is now a standard 20% discount off the list price of most cultures.

Cultures special ordered as test tubes, stabs or flasks, carry an additional laboratory fee of \$50.00 each. Minimum invoicing is \$45.00. Orders received for lesser amounts will be invoiced at the minimum. Prices are in U.S. dollars. Terms: Net 30 from date of invoice. NO COD orders or Letters of Credit accepted. ATCC Accepts VISA, MasterCard and American Express.

**Shipping Charges**

All materials are shipped FOB Manassas, freight prepaid via carrier of our choice and added to your invoice. Packaging is extra.

All ATCC fees for cultures and services are subject to change without notice.

Questions or Comments?

---

Copyright © 2000  
American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209  
All rights reserved.